Company news
NextTrip, Inc. news in 2019
NextTrip, Inc.'s news releases, calls and decks from 2019, newest first.
Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
October 7, 2019
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
September 8, 2019
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
August 12, 2019
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
August 4, 2019
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
July 16, 2019
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
July 14, 2019
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
July 10, 2019
Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
May 29, 2019
Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel
April 18, 2019
Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer
March 31, 2019
Decks in 2019
- Sigma Labs — Investor Presentation (September 2019)
Investor deck · 18 slides · Sep 16, 2019